Anupam Rasayan India Limited delivered exceptional financial results for FY26, with Total Revenue of ₹23,836 million compared to ₹14,485 million in FY25, registering an impressive 65% year-on-year growth. As per the latest financial results, the company achieved its highest-ever annual sales and operating cash flow during the year, reflecting strong business momentum and operational efficiency. Managing Director Anand Desai highlighted that FY26 marked a landmark year as the company continued to strengthen its position as a globally integrated specialty chemicals and CDMO player. The robust performance was supported by higher product commercialization, increasing customer additions, and stronger contributions across key business verticals, providing a solid foundation for the company's major acquisition strategy.
As reported in the latest regulatory filing submitted on May 23, 2026, Anupam Rasayan India Limited has signed a definitive agreement to acquire between 43.3% and 48.2% equity stake in Bliss GVS Pharma Limited, a Mumbai-based pharmaceutical formulations company. Additionally, the company will launch a mandatory open offer to purchase an additional 26 percent stake from public shareholders at the same price. The acquisition will be funded through a ₹300 crore term loan, while the remaining amount will be raised through a non-controlling, non-voting equity instrument. Managing Director Anand Desai confirmed the company has entered into a definitive agreement for the transaction.
This deal marks a major strategic shift for Anupam Rasayan, moving from its traditional role as a custom synthesis and specialty chemicals manufacturer to a more integrated pharmaceutical platform. The acquired business delivered a strong proforma revenue of $95 million, reinforcing the strategic importance of the transaction. The acquisition significantly enhances Anupam Rasayan's global manufacturing footprint, advanced chemistry capabilities, and integrated CDMO platform. The proposed acquisition is expected to create meaningful synergies across CDMO capabilities, product portfolio expansion, and customer relationships, supporting the company's long-term strategy of expanding its pharmaceutical and healthcare-focused business segments. The deal builds on Anupam's earlier acquisition of Jayhawk, enhancing their pharmaceutical capabilities and establishing a North American footprint.
Bliss GVS Pharma, listed on both NSE and BSE, is engaged in the development and export of formulations including suppositories, tablets, capsules and injectables. Incorporated in 1984, the company holds EU-GMP certification and operates manufacturing facilities in Maharashtra and Daman, with approvals from the USFDA and the World Health Organization. The company is globally known for its strong position in suppositories and pessaries, a niche but profitable dosage segment where it owns one of the world's largest product portfolios. Its branded formulations business includes over 150 products across antimalarial, antifungal, antibacterial, anti-inflammatory, and women's healthcare categories, with brands like Lonart, Funbact, and Lofnac having strong presence across Africa, Asia, and Latin America. The acquisition improves the company's access to regulated markets and innovator customers across North America, thereby strengthening its international presence.
Anupam Rasayan India shares traded slightly lower on May 25, 2026, falling nearly 1% to ₹1,353 during intraday trade compared to the previous close of ₹1,366.10, according to latest market data. The stock touched an intraday high of ₹1,390 and a low of ₹1,341.30, with traded value crossing ₹46 crore. The company currently has a market capitalisation of around ₹15,404 crore and trades at a P/E ratio of nearly 70. The company remains optimistic about its future growth trajectory, with increasing contributions from the Performance Materials and Pharma segments, a strong product pipeline, and growing global customer engagements expected to support the next phase of expansion. With strategic acquisitions, operational excellence, and a continued focus on innovation-led growth, Anupam Rasayan India Limited is well-positioned to strengthen its leadership in the specialty chemicals and CDMO space globally.
